Which GLP-1 is best for weight loss? Compare the evidence

The strongest comparison answers a specific question

SURMOUNT-5 found greater mean weight reduction with maximum tolerated tirzepatide 10 or 15 mg than semaglutide 1.7 or 2.4 mg at 72 weeks: −20.2% versus −13.7%. Participants had obesity without type 2 diabetes, and the study was open-label.

Those results do not rank Wegovy HD 7.2 mg, oral Wegovy, or Foundayo, because those formulations were not studied in this comparison. Results from separate trials can be useful context, but differing eligibility, duration, dropout, and analysis methods limit a direct ranking.

Sources: SURMOUNT-5: tirzepatide compared with semaglutide for obesity

Match the condition being treated

Wegovy and Zepbound have weight-management indications, while Ozempic and Mounjaro have type 2 diabetes indications. Additional indications, such as selected cardiovascular or kidney-risk reduction, MASH, or obstructive sleep apnea, belong to specific products and populations.

The presence of an additional diagnosis can change the reason to choose a medicine, what follow-up is needed, and insurance criteria. It should not be turned into a generic claim that every GLP-1 protects every person's heart, kidney, or liver.

Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information

Route, tolerability, and access

Weekly injections and daily tablets create different routines. Oral Wegovy has fasting requirements; Foundayo can be taken with or without food but has its own interactions. Every option requires assessment of contraindications and adverse effects.

A medicine with an impressive average is of limited value if you cannot tolerate it or maintain access. Compare the total recurring bill and plan for follow-up before enrollment. An advertised compounded product is not a clinically proven equivalent to a branded drug.

Sources: Wegovy prescribing information, including tablets and Wegovy HD · Foundayo prescribing information · FDA concerns with unapproved GLP-1 drugs used for weight loss

Safety before any dose change

These medicines have boxed warnings about thyroid C-cell tumors observed in rodents; whether the same risk occurs in humans is unknown. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. This is different from saying that every thyroid condition prevents treatment.

Review severe stomach problems, previous pancreatitis, gallbladder disease, kidney problems, diabetes-related eye disease, pregnancy plans, and all medicines with your prescriber. Insulin or sulfonylureas can increase the risk of low blood sugar when combined with these treatments. Vomiting and diarrhea can cause dehydration and kidney injury.

Severe persistent abdominal pain, inability to keep fluids down, or signs of an allergic reaction require prompt medical assessment. Do not increase a dose to overcome slow weight loss or copy another person's prescription. Tell the anesthesia team about treatment before procedures because delayed gastric emptying can affect aspiration risk.

Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information

Build a decision around the outcome that matters

Start with the health problem the clinician is treating. Weight management, diabetes, cardiovascular risk, sleep apnea, and MASH can point to different product-specific evidence. Then consider contraindications, other medicines, tolerability, and whether the daily or weekly routine is realistic. Only after those questions does a weight-loss ranking become useful. A drug with a larger average reduction may still be a poor practical fit for someone who cannot safely use or sustain it.

Ask the clinician to compare two or three plausible options for your situation rather than every product on the market. A good comparison explains the likely benefit, the strongest relevant evidence, the main safety concerns, the administration task, and the full recurring cost. It should identify uncertainty rather than give a universal winner based on a single percentage. No product guarantees the trial average.

Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information · NIDDK: prescription medications to treat overweight and obesity

Three common mistakes in weight-loss comparisons

First, comparing a study in people without diabetes with one in people with diabetes can overlook an important population difference. Second, comparing different durations or analyses can make percentages look more directly comparable than they are. Third, comparing the largest dose of one medicine with a lower dose of another may answer a narrower question than a headline suggests.

SURMOUNT-5 avoids some problems by directly comparing two regimens in one obesity study, but it still does not include Wegovy HD, oral Wegovy, or Foundayo. It cannot settle a ranking of every current option. Also distinguish average weight change from the percentage of participants achieving a milestone. A claim that many participants reached a threshold does not mean that every participant, or an individual reader, experienced that amount of loss.

Sources: SURMOUNT-5: tirzepatide compared with semaglutide for obesity · Wegovy prescribing information, including tablets and Wegovy HD · Foundayo prescribing information

Compare care pathways as well as molecules

A hypothetical person with reliable coverage for one approved treatment and no coverage for another faces a continuity issue that a trial chart cannot solve. A different person may need a multidisciplinary program because nutrition, symptoms, or diabetes management require more support. Program quality should be evaluated through actual services and access, not inferred from which molecule appears on its website.

Get a maintenance quote and find out who handles authorization, refills, and urgent symptoms. If a program proposes compounding, evaluate that as a separate formulation and regulatory decision; approved-product trial results do not automatically apply. Ask why an approved drug does not meet the medical need and identify the dispensing pharmacy. The best sustainable plan combines an appropriate medicine with clear follow-up, realistic access, and a patient who can use it as prescribed.

Sources: Ro weight-loss program pricing · Form Health official website · FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes